Description
An androgen receptor antagonist (IC50 = ~6 μM for inhibition of transactivation of the androgen receptor NTD); inhibits androgen-, FSK-, and IL-6-induced, as well as ligand-independent, PSA reporter gene expression in LNCaP cells expressing either the full length androgen receptor or a constitutively active mutant that lacks the ligand binding domain in a dose-dependent manner; inhibits androgen receptor interaction with the PSA androgen response element and blocks androgen-stimulated induction of endogenous PSA and 17 other androgen regulated genes in LNCaP cells; inhibits androgen-dependent and -independent growth of LNCaP and MDA-PCa-2B cells, but not 22Rv1, DU145, or PC3 cells that do not express the androgen receptor; reduces serum PSA and tumor growth in an LNCaP prostate cancer xenograft model in castrated mice when administered at a dose of 50 mg/kg,
Formal name: 3-[4-[1-[4-(3-chloro-2-hydroxypropoxy)phenyl]-1-methylethyl]phenoxy]-1,2-propanediol
Synonyms:
Molecular weight: 394.9
CAS: 227947-06-0
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Hormones & Receptors|Androgens